On November 18, 2025, major financial media reported that Eli Lilly's weight-loss drug Zepbound is on track to become the world's top-selling drug, helping propel the company toward a $1 trillion market capitalization. This development underscores strong investor optimism about Lilly's future growth and the transformative impact of its obesity and diabetes portfolio. No specific price movement data is available for November 18, 2025, but the news coverage suggests that Zepbound's commercial success and the company's market cap milestone are key drivers of recent positive sentiment around the stock.